Role of new antifungal agents in prophylaxis of mycoses in high risk patients
- PMID: 16258319
- DOI: 10.1097/01.qco.0000185984.57135.ad
Role of new antifungal agents in prophylaxis of mycoses in high risk patients
Abstract
Purpose of review: For pancreas, liver, and hematopoietic stem cell transplant recipients, no antifungal prophylaxis led to a high rate of and high morbidity from fungal infection. With the use of fluconazole as prophylaxis since the early 1990s, there have been shifts in the types of infecting fungal pathogens, documentation of resistance among fungal organisms, and changes in transplant practices. The aim of this article is to review recent clinical trials regarding antifungal chemoprophylaxis among several populations of high risk patients.
Recent findings: Itraconazole, micafungin, and posaconazole have been studied as alternatives to fluconazole prophylaxis. Itraconazole showed no dramatic improvement over fluconazole as prophylaxis during liver and hematopoietic stem cell transplantation, primarily due to gastrointestinal side effects. In addition, detrimental changes to cyclophosphamide metabolism were noted for hematopoietic stem cell transplant recipients. Micafungin was superior to fluconazole during the pre-engraftment period of hematopoietic stem cell transplantation, because it was able to prevent mold infections, required less switches to empirical antifungal therapy, and functioned as well as fluconazole in preventing yeast infections. Posaconazole was compared to fluconazole during a 16-week prophylaxis period during graft-versus-host disease, but results of this study are still forthcoming. Aerosolized amphotericin products appear to be safe for lung transplant recipients.
Summary: Fluconazole remains the standard agent for prophylaxis against invasive fungal infections for pancreas, liver, and hematopoietic stem cell transplant recipients. Micafungin is superior to fluconazole with minimal toxicity for use in the pre-engraftment period of hematopoietic stem cell transplantation. The optimal agent for prophylaxis later following transplant, if mold coverage is desired during prolonged immunosuppression, has not been determined.
Similar articles
-
Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.Clin Ther. 2014 Feb 1;36(2):292-306.e1. doi: 10.1016/j.clinthera.2013.11.010. Epub 2014 Jan 17. Clin Ther. 2014. PMID: 24439393
-
Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.Ann Intern Med. 2003 May 6;138(9):705-13. doi: 10.7326/0003-4819-138-9-200305060-00006. Ann Intern Med. 2003. PMID: 12729424 Clinical Trial.
-
Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.Expert Rev Anti Infect Ther. 2006 Jun;4(3):457-68. doi: 10.1586/14787210.4.3.457. Expert Rev Anti Infect Ther. 2006. PMID: 16771622 Review.
-
Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients.Drugs Today (Barc). 2008 Jul;44(7):515-30. doi: 10.1358/dot.2008.44.7.1230943. Drugs Today (Barc). 2008. PMID: 18806902 Review.
-
Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.Pharmacotherapy. 2009 Nov;29(11):1306-25. doi: 10.1592/phco.29.11.1306. Pharmacotherapy. 2009. PMID: 19857148 Review.
Cited by
-
Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.Drugs. 2008;68(15):2225-55. doi: 10.2165/00003495-200868150-00010. Drugs. 2008. PMID: 18840009 Review.
-
Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.Antimicrob Agents Chemother. 2009 Jul;53(7):3140-2. doi: 10.1128/AAC.00213-09. Epub 2009 Apr 20. Antimicrob Agents Chemother. 2009. PMID: 19380591 Free PMC article.
-
Invasive Fungal Infections While on Voriconazole, Liposomal Amphotericin B, or Micafungin for Antifungal Prophylaxis in Pediatric Stem Cell Transplant Patients.J Pediatr Pharmacol Ther. 2019 May-Jun;24(3):220-226. doi: 10.5863/1551-6776-24.3.220. J Pediatr Pharmacol Ther. 2019. PMID: 31093021 Free PMC article.
-
A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key.Front Pediatr. 2021 Jul 27;9:634449. doi: 10.3389/fped.2021.634449. eCollection 2021. Front Pediatr. 2021. PMID: 34386464 Free PMC article. Review.
-
Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?Ther Clin Risk Manag. 2008 Dec;4(6):1261-80. doi: 10.2147/tcrm.s3994. Ther Clin Risk Manag. 2008. PMID: 19337433 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials